Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Acute Myeloid Leukemia AML

Watch Session

330 The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results

David A. Sallman, Adam S. Asch, Suman Kambhampati, et al.

 

331 Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Ibrahim Aldoss, Geoffrey L Uy, Norbert Vey, et al.

 

332 Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML  according to ASH clinically relevant abstract

Curtis Lachowiez, Marina Konopleva, Tapan M. Kadia, et al.

 

333 Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, Jessica K. Altman, Joseph Maly, et al. 

 

334 Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Alexander E. Perl, Jessica K. Altman, Naoko Hosono, et al.

 

335 Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I Versus Type II FLT3-Inhibitors (FLT3i’s)

Ahmad S. Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.